Liporaxel (Paclitaxel) Gains Approval for New Breast Cancer Indication
MFDS approved Liporaxel (paclitaxel) for first-line treatment of recurrent or metastatic HER2-negative breast cancer (approval date: 2026-05-13)
Expansion from existing gastric cancer indication to breast cancer, based on phase 2/3 clinical trial results
Oral paclitaxel formulation offers convenience, expected to improve quality of life
Company plans to establish out-licensing strategy
KOSDAQ Filing Information
Filing: Major Management Matters for Investment Judgment (Approval of Change in Product License for Liporaxel (Paclitaxel) (Approval of New Indication Addition for Breast Cancer))